Results 151 to 160 of about 28,270 (206)

Comparison of efficacy and safety between TIcagrelor and clopidogrel in Chinese patients with acute coronary syndrome (COSTIC study). [PDF]

Int J Cardiol Heart Vasc
Huang M, Sun Y, Li K, Yu T, Zhao H, Tao M, Song X, Wang L, Xu X, Chen Y, Cui G, Ding H, Yan J, Jiang J, Zeng H, Wang Y, Shen X, Wang H, Wang DW.   +18 more
europepmc   +1 more source

"Reconsidering CYP3A4/5 Genotyping for Ticagrelor Safety: Critical Appraisal of a Narrow Genetic Framework". [PDF]

Clin Cardiol
Tahir I, Shahbaz H.
europepmc   +1 more source

Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.

Cardiorenal Med
Sun WC, Lee HF, Lin C, Huang SC, Chen JJ, Ho WY, Yen CL, Hsiao CC.   +7 more
europepmc   +1 more source

Unveiling the Hidden Risk: Ticagrelor-Induced Bradyarrhythmias and Conduction Complications in ACS Patients-Case Series. [PDF]

J Cardiovasc Dev Dis
Gorzynska-Schulz A, Stencelewski D, Daniłowicz-Szymanowicz L, Lica-Gorzynska M, Firkowska A, Wabich E.   +5 more
europepmc   +1 more source

Is Ticagrelor-Related Dyspnea a Liability or a Biomarker of Response? [PDF]

Clin Cardiol
Birgün A, Sarıhan A, Kalçık M.
europepmc   +1 more source

Ticagrelor-Loaded Phospholipid-Polyoxyethylene Hybrid Nanocarriers: Enhanced Solubility and Efficacy Against SARS-CoV-2. [PDF]

Pharmaceuticals (Basel)
Katamesh AA, Sayed OM, Almansour K, Hassoun SM, Subaiea GM, Boseila AA.   +5 more
europepmc   +1 more source

Implementing a CYP2C19-guided approach for prescribing dual antiplatelet therapy in acute coronary syndrome for patients undergoing percutaneous coronary intervention: a cost-effectiveness analysis

Mahboub-Ahari A, Hilton J, Rodrigues M, McDermott J, Body R, Newman WG, Payne K.   +6 more
europepmc   +1 more source

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack. [PDF]

Stroke
Lin J, Zhou H, Wang Y, Jin A, Li S, Zhang L, Meng X, Xie X, Jing J, Jiang Y, Wang Y, Zhao X, Li H, Li Z, Wang Y, CHANCE-2 Investigators.   +15 more
europepmc   +1 more source

Establishing FDA-approved oncology drugs as GPR176 inhibitor through homology modelling, molecular docking, MMGBSA, DFT, and molecular dynamics simulation. [PDF]

Sci Rep
Ishabiyi FO, Umar HI, Dutta T, Onyinye OC, Damola OD, Budagova L, Temesgen D, Bourhia M, Bello RO, Alyami EM, Alsolami M, Almohammed OA.   +11 more
europepmc   +1 more source